San Diego-based RNA drug developer ADARx Pharmaceuticals has launched its U.S. initial public offering, seeking a valuation of up to $1.74 billion as momentum builds across clinical-stage biotech listings.
Key Data & Offering Highlights:
- Capital Target: Aiming to raise up to $371.9 million by offering 21.9 million shares priced between $15 and $17.
- Pharma Backing: AbbVie agreed to a concurrent $100 million private placement for a ~4.9% post-IPO stake, building on its $335M research partnership in May 2025.
- Clinical Pipeline: Features 3 clinical and 2 advanced preclinical programs. Lead drug candidate onvuzosiran is in late-stage testing for hereditary angioedema (a rare genetic disorder).
- Listing Details: Underwritten by JPMorgan, Morgan Stanley, and TD Cowen; will list on the Nasdaq under ticker “ADRX”.
- Biotech IPO Climate: Joins a selective rebound favoring clinical-stage developers with late-stage assets and strong pharma validation, alongside recent listings like Electra Therapeutics ($350M raised).
A strong validation of RNA-based therapeutics as big pharma continues to fund advanced clinical innovation! 📊🔬🇺🇸